Nasdaq

Biosense Webster Receives FDA Approval for THERMOCOOL SMARTTOUCH® SF Ablation Catheter for the Treatment of Persistent Atrial Fibrillation

The CARTO® 3 System and THERMOCOOL SMARTTOUCH® SF Catheter allow for a patient-tailored ablation approach, resulting in high long-term effectiveness in persistent atrial fibrillation patients* IRVINE, ...
Business Wire

Biosense Webster Successfully Completes First Clinical Atrial Fibrillation Ablation Cases in the European Union Using the THERMOCOOL ® SMARTTOUCH™ Contact Force Sensing Catheter

DIAMOND BAR, Calif.--(BUSINESS WIRE)--Biosense Webster, Inc., a Johnson & Johnson company, and a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the successful ...
Nasdaq

Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium

IRVINE, Calif., Feb. 2, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced 12-month results from the company ...
FiercePharma

Biosense Webster Receives FDA Clearances for the CARTOXPRESS™ Software Module and LASSO® NAV Catheter for its CARTO®

State-of-the-Art Software and new sensor-enabled catheter provides Electrophysiologists with an unparalleled level of speed and visualization in their 3D Mapping and Ablation procedures. FAM is a ...
FiercePharma

Biosense Webster Enrolls First Patient in Groundbreaking SMART-AF Trial

Completes First Atrial Fibrillation Ablation Case in the United States Using The THERMOCOOL ® SMARTTOUCH ™ Contact Force Sensing Catheter & Software Module DIAMOND BAR, Calif.--(BUSINESS WIRE)-- ...
Business Wire

Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant Patient Benefits Demonstrated by Company’s Leading Contact Force Therapy

DIAMOND BAR, Calif.--(BUSINESS WIRE)--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the BIOSENSE WEBSTER ADVANTAGE SM ...
TCTMD

Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping System

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO™ 3 System Version 8, the latest version of the company's ...
News Medical

Biosense Webster enrolls and treats first patient in QDOT AF study

Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in ...
TCTMD

Biosense Webster Announces Initial Results From First In-Human Study Of Novel High Power-Short Duration Ablation Catheter For Atrial Fibrillation

SAN FRANCISCO – Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc.’s QDOT MICRO, a novel catheter that facilitates high power-short duration radiofrequency (RF) ...
PharmiWeb

Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

Industry’s highest density fixed array mapping catheter, covering the largest area in a fixed matrix format, can help physicians effectively map in a shorter procedure time IRVINE, CA – July 24, 2023 ...
Seeking Alpha

Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping System

Increases efficiency, reproducibility, and accuracy i in the electro-anatomical maps electrophysiologists use in catheter ablation procedures IRVINE, Calif., May 8, 2024 /PRNewswire/ -- Biosense ...